Transarterial chemoembolisation enhances programmed death‐1 and programmed death‐ligand 1 expression in hepatocellular carcinoma
| العنوان: | Transarterial chemoembolisation enhances programmed death‐1 and programmed death‐ligand 1 expression in hepatocellular carcinoma |
|---|---|
| المؤلفون: | Olivier Soubrane, Aurélie Beaufrère, Ahmed Montasser, Miguel Albuquerque, Mohamed Bouattour, Valérie Paradis, François Cauchy |
| المصدر: | Histopathology. 79:36-46 |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, 0301 basic medicine, medicine.medical_specialty, Carcinoma, Hepatocellular, Histology, Combination therapy, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Gastroenterology, B7-H1 Antigen, Pathology and Forensic Medicine, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, PD-L1, Internal medicine, Biomarkers, Tumor, Humans, Medicine, Chemoembolization, Therapeutic, Aged, Aged, 80 and over, biology, business.industry, Liver Neoplasms, General Medicine, Immunotherapy, Middle Aged, HCCS, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, biology.protein, Immunohistochemistry, Female, Programmed death 1, Transcriptome, business, Programmed death |
| الوصف: | AIMS Immunotherapies represent a new alternative therapeutic approach for hepatocellular carcinomas (HCCs), and have shown promising results when used in combination therapy. The aim of this study was to evaluate the potential of transarterial chemoembolisation (TACE) to modulate programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression profiles in a cohort of surgically treated HCCs. METHODS AND RESULTS A total of 82 surgically treated HCCs from patients who had undergone (n = 32) or not undergone (n = 50) preoperative TACE were included in the study. Immunohistochemical expression of PD-1 and of PD-L1 were analysed and compared according to TACE treatment. Pretreatment biopsies, which were available for 30 cases (20 with TACE and 10 without), were similarly analysed. Follow-up data were retrieved from patients' charts. PD-1 expression (≥1%) in intratumoral inflammatory cells (ICs) was observed in 46% of HCCs, and PD-L1 expression (≥1%) in ICs and PD-L1 expression in tumour cells (TCs) were observed in 46% and 16% of HCCs, respectively. A low level of PD-1 expression ( |
| تدمد: | 1365-2559 0309-0167 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de3b8190900c797687dcf60d91de283Test https://doi.org/10.1111/his.14317Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....0de3b8190900c797687dcf60d91de283 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652559 03090167 |
|---|